A separate Prime analysis, however, of year-over-year claims data for Wegovy and Zepbound only found an improvement in ...

It would behoove more Americans to learn how consistent seafood consumption has strong potential to ward off coronary disease ...

A clinical guidance from the American College of Cardiology Solution Set Oversight Committee states that pharmacotherapy may ...

Eli Lilly poised for 30-50% growth in 12 months with a strong value and growth nexus. Click here to read more on LLY stock.

A $10.2 million savings across more than 100,000 prescriptions over three months, extrapolated across the nearly 33 million Americans currently taking GLP-1 medications monthly, indicates a potential ...

If you’re considering using medication to reach a healthy body weight, your first question might be: Are weight loss drugs covered by insurance? The short answer: Sometimes, but not always.

Detailed price information for Eli Lilly and Company (LLY-N) from The Globe and Mail including charting and trades.

A new study reports that people taking GLP-1 drugs in daily life don’t lose as much weight as those in clinical trials who ...

The next generation of diabetes and weight loss drugs could come in pill form, deliver even greater weight loss results, and ...

New data from a Phase 3 trial show that the daily anti-obesity pill may be as safe and effective as drugs like Mounjaro and ...

At a time when Novo Nordisk has appeared to be slipping behind rival Eli Lilly and its blockbuster Zepbound (tirzepatide) in ...

The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $943.0, a high ...